Tocilizumab Versus Baricitinib for the Treatment of COVID-19 in Patients With Obesity
Journal of Pharmacy Practice · 2024
DOI: 10.1177/08971900231158931 ↗Kurz gefasst
Vergleichsstudie in der Zeitschrift Journal of Pharmacy Practice, 2024. Verfasst von Bradley S Troyer und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacy Practice, University of Charleston School of Pharmacy, Charleston, WV, USA. Hauptthemen laut MEDLINE: COVID-19 Drug Treatment, Obesity, Sulfonamides, Azetidines. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 13 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.
Abstract (Originalsprache)
Background
Tocilizumab and baricitinib have emerged as potential treatments for patients infected with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) following the findings of the Recovery Group and the results of the COV-BARRIER study. Unfortunately, there is a lack of guidance regarding the use of these agents in high-risk patients, such as those with obesity.
Objective
To compare the outcomes of tocilizumab and baricitinib as potential treatments for obese patients infected with SARS-CoV-2.
Methods
This was a multi-center retrospective analysis comparing outcomes of obese patients who received the standard of care plus tocilizumab or baricitinib for the treatment of SARS-CoV-2. Included patients had a BMI >30 kg/m 2 , needed ICU level care, and required non-invasive or invasive ventilatory support.
Results
This study included 64 patients who received tocilizumab and 69 patients who received baricitinib. When examining the primary outcome, patients who received tocilizumab had a shorter duration of ventilatory support (10.0 vs 15.0 days, P = .016) than patients who received baricitinib. Our secondary outcome of in-hospital mortality was lower in the tocilizumab group as well (23.4% vs 53.6%, P < .001). Tocilizumab was also associated with a non-significant reduction in new positive blood cultures (13.0% vs 3.1%, P = .056) and new invasive fungal infection (7.3% vs 1.6%, P = .210).
Conclusions
This retrospective review showed a reduced duration of ventilatory support in obese patients who received tocilizumab vs baricitinib. In the future, additional studies should be conducted to further examine and confirm these results.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pharmacy Practice, University of Charleston School of Pharmacy, Charleston, WV, USA.
- Critical Care Pharmacy Department, West Virginia University Hospitals, Morgantown, WV, USA.
ORCID-Profile: Bradley S Troyer
Zitieren
APA
Troyer, B. S., Kovacic Scherrer, N., & Garavaglia, J. (2024). Tocilizumab Versus Baricitinib for the Treatment of COVID-19 in Patients With Obesity. Journal of Pharmacy Practice. https://doi.org/10.1177/08971900231158931
Vancouver
Troyer BS, Kovacic Scherrer N, Garavaglia J. Tocilizumab Versus Baricitinib for the Treatment of COVID-19 in Patients With Obesity. Journal of Pharmacy Practice. 2024. doi:10.1177/08971900231158931
BibTeX
@article{Troyer2024,
author = {Troyer, Bradley S and Kovacic Scherrer, Nicole and Garavaglia, Jeffrey},
title = {Tocilizumab Versus Baricitinib for the Treatment of COVID-19 in Patients With Obesity},
journal = {Journal of Pharmacy Practice},
year = {2024},
doi = {10.1177/08971900231158931}
}
EUVIMED